Business
Todos Medical Announces Publication Demonstrating Potential of FTIR Platform to Identify Bacterial and Viral Infections
Todos Medical Announces Publication Demonstrating Potential of FTIR Platform to Identify Bacterial and Viral Infections.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n Todos evaluating applying its proprietary FTIR platform towards the novel coronavirusSeeking appropriate partners to get access to patient samples to train its AI platform REHOVOT, Israel and NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a pre-commercial stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced the publication of data from a human clinical study in the scientific journal Analytical Chemistry entitled “Differential Diagnosis of the Etiologies of Bacterial and Viral Infections Using Infrared Microscopy of Peripheral Human Blood Samples and Multivariate Analysis”. The data demonstrate that the use of the Fourier-transform infrared (FTIR) spectroscopy technique on peripheral blood samples yields a differential diagnosis when seeking to make a clinical diagnosis between patients with viral infections, bacterial infections and healthy controls. “With the recent explosion of novel coronavirus (2019-nCoV) worldwide, definitively diagnosing viral infections versus bacterial or other types of infections that present with similar symptoms has become paramount in order to appropriately triage patients and guide treatment decisions for healthcare professionals,” said Gerald Commissiong, President & CEO of Todos Medical. “Todos’ proprietary FTIR blood testing platform that focuses on the immune system’s reaction to cancer has received CE Marks in Europe for the diagnosis of breast cancer and colon cancer, has recently achieved strong analytical performance results from our proprietary sample preparation methods, and is currently enrolling a pre-commercial breast cancer study in Romania with distribution partner Orot+ (a division of Orot Luces) ahead of an expected commercial launch in Romania later this year. Based on these recent successes and this publication from the Company’s licensors at Ben Gurion University, we have now formally begun to evaluate the commercial feasibility of applying our technology towards the diagnosis of bacterial and viral infections, including coronavirus. Because we use AI to create the algorithms required to differentially diagnosis cancer, we believe the rate limiting step towards creating algorithms for vi...